Cohance Lifesciences Ltd
Cohance Lifesciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #39 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Management remains committed to the USD 1 billion sales target by FY '30, though timing may shift slightly due to current challenges. FY '27 is expected to be a year of growth, driven by successful pipeline progression and recovery in the API Plus segment (Page 8).
From Cohance Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Management remains committed to the USD 1 billion sales target by FY '30, though timing may shift slightly due to current challenges.
- FY '27 is expected to be a growth year, driven by recovery in API Plus segment and pipeline progression across API and formulation businesses.
- Increased traction in RFQs, including late-stage and commercial ones, is expected to translate into new business starting FY '27 and growing progressively.
- Pipeline of early-stage commercial assets is strong, supporting expected value creation over the next 10 years.
- Specialty Chemicals business is anticipated to improve earnings in FY '27 as qualification programs mature.
2 more points from Cohance Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Cohance Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure during the first nine months of FY26 amounted to INR161 crore.
- Investments primarily directed towards advancing differentiated platforms such as ADC (Antibody Drug Conjugates) and oligonucleotides.
- Strengthening quality and compliance systems is a key investment focus.
- Selective capacity and capability upgrades aligned with customer programs undertaken.
- Continuous investment in leadership, business development, quality, and technology platforms.
- Investment to support a broader and more complex pipeline, especially in the API Plus segment.
- Emphasis on enhancing technology-led CRDMO platform through quality systems, regulatory capabilities, and complex chemistry platforms.
2 more points from Cohance Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cohance Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Pharma CDMO business has seen a meaningful increase in late-stage RFP activity from both new and existing customers, with a double-digit number of commercial and late-stage RFPs secured recently.
- The business development team was completed in December, leading to strengthened prospects for FY '27.
- The Q4 order book remains healthy and consistent with seasonally stronger demand profiles.
- Pipeline across API and formulation is broader, showing significant improvement in inquiry flow.
- RFQ conversion rate is around 20%, with much higher RFQ volumes for Phase 3 and commercial projects.
- Orders from new customer engagements and existing programs are expected to start yielding business progressively through FY '27.
2 more points from Cohance Lifesciences Ltd's call on order book
Create a free account to keep reading this call
Cohance Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cohance Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cohance Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cohance Lifesciences Ltd Q3 FY26 results?
Management remains committed to the USD 1 billion sales target by FY '30, though timing may shift slightly due to current challenges. FY '27 is expected to be a year of growth, driven by successful pipeline progression and recovery in the API Plus segment (Page 8).
What is Cohance Lifesciences Ltd share price analysis?
Cohance Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 152.6 with a market cap of ₹16,429 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cohance Lifesciences Ltd planning capital expenditure?
Capital expenditure during the first nine months of FY26 amounted to INR161 crore.
Keep Cohance Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.